Geron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025

Reuters

2025/11/03

Geron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025

Geron Corporation has announced that five presentations highlighting the clinical activity of RYTELO® (imetelstat) in myeloid hematologic malignancies have been accepted for the 67th American Society of Hematology $(ASH)$ 2025 Annual Meeting, scheduled for December 6-9, 2025, in Orlando, FL. The accepted abstracts include one oral and four poster presentations, featuring new clinical and translational analyses of imetelstat in lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF). Among the presentations, an oral session will discuss the correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with LR-MDS, based on data from the IMerge Trial. Additionally, interim results from an investigator-led study of imetelstat in high-risk MDS will be presented as a poster, indicating limited single-agent activity in this patient group. These results are scheduled to be presented at the ASH 2025 meeting and have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103126919) on November 03, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580721961"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580721961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580721961?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580721961","market":"fut","top_or_hot":-1,"title":"Geron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Geron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Geron Corporation has announced that five presentations highlighting the clinical activity of RYTELO® (imetelstat) in myeloid hematologic malignancies have been accepted for the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> 2025 Annual Meeting, scheduled for December 6-9, 2025, in Orlando, FL. The accepted abstracts include one oral and four poster presentations, featuring new clinical and translational analyses of imetelstat in lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF). Among the presentations, an oral session will discuss the correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with LR-MDS, based on data from the IMerge Trial. Additionally, interim results from an investigator-led study of imetelstat in high-risk MDS will be presented as a poster, indicating limited single-agent activity in this patient group. These results are scheduled to be presented at the ASH 2025 meeting and have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103126919) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Geron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-03 22:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Geron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Geron Corporation has announced that five presentations highlighting the clinical activity of RYTELO® (imetelstat) in myeloid hematologic malignancies have been accepted for the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> 2025 Annual Meeting, scheduled for December 6-9, 2025, in Orlando, FL. The accepted abstracts include one oral and four poster presentations, featuring new clinical and translational analyses of imetelstat in lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF). Among the presentations, an oral session will discuss the correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with LR-MDS, based on data from the IMerge Trial. Additionally, interim results from an investigator-led study of imetelstat in high-risk MDS will be presented as a poster, indicating limited single-agent activity in this patient group. These results are scheduled to be presented at the ASH 2025 meeting and have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103126919) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GERN","symbol_name":"傑龍","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDLSLN3h:1","article_id":"2580721961","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580721961","pubTimestamp":1762178729,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via Business Wire  on November 03, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GERN":"杰龙","BK4139":"生物科技"},"translate_title":"Geron在ASH 2025上重点介绍RYTELO在髓系恶性肿瘤中的新临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GERN":0.9},"content_text":"Geron Highlights New RYTELO Clinical Data in Myeloid Malignancies at ASH 2025\n    \n\n        Geron Corporation has announced that five presentations highlighting the clinical activity of RYTELO® (imetelstat) in myeloid hematologic malignancies have been accepted for the 67th American Society of Hematology $(ASH)$ 2025 Annual Meeting, scheduled for December 6-9, 2025, in Orlando, FL. The accepted abstracts include one oral and four poster presentations, featuring new clinical and translational analyses of imetelstat in lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF). Among the presentations, an oral session will discuss the correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with LR-MDS, based on data from the IMerge Trial. Additionally, interim results from an investigator-led study of imetelstat in high-risk MDS will be presented as a poster, indicating limited single-agent activity in this patient group. These results are scheduled to be presented at the ASH 2025 meeting and have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103126919) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}